Life Sciences

Medicare Reform Advisor, February 10, 2004

Medicare Reform Advisor, February 10, 2004



February 10, 2004
Vol. 1, No. 1

Weekly news and analysis



THIS WEEK'S FEATURE


Emergency docs can now order tests without denial worry

TOP STORIES
  1. DOJ to enforce drug card regs

  2. Sales average payment system may change

  3. CMS releases infusion, dialysis updates

  4. CMS Breaking News

  5. What new treatment regimens could look like for practices

  6. Managed care plans must create fraud & abuse control

    SUBSCRIBE
    to Medicare Reform Advisor

    MEDICARE MURMURS

    "To be paid for oncology drugs at the average sales price plus (ASP) 6% will lead to layoffs and put us out of business. We need to be at ASP plus 12%."

    -Steven Coplon, chief executive officer, the West Clinic in Memphis, TN, on what he believes must happen to the Medicare reform law to save cancer care providers.

    Editor's note: Average sales price (ASP) will be the new system under the MMA to reimburse providers for administering outpatient drugs. CMS will determine ASP on a quarterly basis starting in 2005. ASP is supposed to be an average of final sales prices to all U.S. purchasers, net of rebates and other discounts. Though, as pricing economist Mick Kolassa wonders, "How can we have average sales without sales?" Manufacturers that misrepresent this data will pay civil money penalties.

    STUDY
    Abuse prevention part of $25 million long-term care pilot

    LETTERS TO THE EDITOR

    Send letters to bcote@hcpro.com. Include tips, ideas, questions, and problems related to Medicare reform. The editors reserve the right to edit letters for clarity.

    DATEBOOK

    February 15-Deadline for hospitals to appeal for geographic reclassification. For urban hospitals, the distance from the hospital to the area where they want to be reclassified cannot exceed 15 mi.; for rural hospitals, the distance cannot exceed 35 mi. Contact the editor for application information.

    February 17-The Department of Health and Human Services is expected to send a letter and fact sheet on MMA to all Medicare beneficiaries.

    April 1-CMS to report diagnosis and procedure codes for new medical technology under inpatient hospital prospective payment system.

    © 2004 HCPro, Inc.

    Exclusive report

    From the Advisory Panel on Medicare Education - February 5 Meeting, Washington, DC

    Senior advocacy groups are worried that Medicare drug debit cards, which will officially be available in June, will be an invitation for fraud. Some seniors in New York state have already reported receiving letters for fake cards touting "Medicare approved" information. The Centers for Medicare & Medicaid Services (CMS) is concerned, but agency officials made it clear February 5 that the debit card program will last "just 18 months," so CMS' job now is to pick the best sponsors and gear up for the 2006 drug benefit.

    DOJ to enforce 'drug card' regs

    The Department of Justice (DOJ) and a handpicked CMS "program safeguard" contractor will make sure drug card sponsors, their pharmacy benefit managers, and network pharmacies follow Medicare Modernization Act (MMA) rules, according to Michael McMullan, CMS' deputy director for beneficiary education.

    CMS will pick the sponsors by March from 106 applicants (the agency could choose all 106). Under MMA, these sponsors must secure rebates and discounts on covered drugs and then pass on a share of the savings to seniors who are enrolled in the debit card system. All sponsors must implement a grievance process; expect the DOJ and Office of Inspector General (OIG) to use complaints to help it identify abuse and noncompliance. The OIG has authority to impose civil money penalties or revoke a contract if it can prove noncompliance, according to the MMA.

    Five key rules for drug card sponsors

    1. At least 90% of beneficiaries in urban areas live within 2 mi of the retail pharmacies in each sponsor's network; for suburban areas, the rule is 5 mi. In rural areas, 70% of beneficiaries must live within 15 mi of a participating pharmacy.

    2. At the point of sale, network pharmacies must report the price difference between the brand and the equivalent generic the pharmacy offers. CMS representatives are not clear on how pharmacies must do this.

    3. Sponsors must report monthly to CMS any price changes in drugs covered through the cards. Medicare Reform Advisor will post these changes monthly.

    4. Covered drugs include syringes, needles, alcohol swabs, and gauze associated with the injection of insulin, says CMS' Cynthia Moreno.

    5. The Health Insurance Portability and Accountability Act of 1996: Sponsors must follow all privacy provisions. For example, mailings to drug card beneficiaries cannot contain anything unrelated to the card.

    Back to top


    Drug Reform Analysis

    Sales average payment system may change

    The good news: The perplexing average wholesale price system to reimburse for drugs administered in the outpatient setting will go away in 2006. The not-so-good news: The new MMA system based on acquisition costs that you're expecting may change before it starts.

    "The new average sales price system will likely be adjusted, perhaps in the next 12 months," said former CMS administrator Tom Scully on January 14 during a private meeting of pharmaceutical companies in Washington, DC. But many expect the 2004 presidential election to get in the way of any significant changes to the legislation.

    However, Mick Kolassa, PhD, managing partner at Medical Marketing Economics, predicts some bumps in the road."CMS wants a net-based, actual acquisition cost system, but current reporting services such as First Data Bank don't provide that and aren't equipped to do so. Wholesalers could provide this, though."

    Back to top


    CMS releases infusion, dialysis updates

    Use the KD modifier to identify any infusion drugs given this year during a durable medical equipment implantation, according to CMS transmittal 75 released January 30. The payment limit for these drugs is 95% of the average wholesale price (AWP) published October 1, 2003, even when the provider didn't implant the equipment. Most drugs and biologicals not paid on a cost or prospective payment basis are based on 85% of AWP based on published compendia as of April 1, 2003. There are some payment limit exceptions for drugs and biologicals in effect for 2004 only:

    1. The following will be paid at 95% of AWP based on published compendia from September 1, 2003:

    • Blood clotting factors
    • Dialysis-related vaccines
    • Influenza vaccines
    • Pneumococcal vaccines
    • Hepatitis B vaccines

    2. New drugs or biologicals without AWP listings will be paid at 95% of AWP from published compendia on the first day of the month that the payment limit for the drug or biological is determined. New drugs are not currently covered by a specific health care common procedural coding system code.

    3. Drugs and biologicals not described above will be paid at 85% of the AWP reflected in the published compendium as of April 1, 2003.

    CMS sent a notice regarding these updates to Medicare-contracted carriers and fiscal intermediaries. Contractors cannot, under the MMA, search their files to retroactively pay claims or retract payment for claims they already paid. However, they may adjust claims brought to their attention.

    Back to top


    CMS Breaking News

    Ambulance

    The following two big changes to improve access to medical emergency ground transportation service take effect July 1:

    1. Ambulance providers that start trips in ZIP codes chosen by CMS to be critical rural areas will receive increased payment. Contractors must identify rural areas that qualify for the bonus with a "B" on the national ZIP code file. Effective through 2009.

    2. A 25% bonus applied to the Medicare ambulance fee schedule for each mile that providers drive above 50 mi for trips that originate in rural and urban areas. Effective through 2008.

    Part A coverage

    Medicare summary notices must list the number of remaining days in a patient's Part A skilled nursing benefit. These include skilled nursing claims for post-hospital extended care services under Part A. Effective July 6.

    Hospitals

    Hospitals have until July 1 to submit data to their quality improvement organizations (QIO). Data must be reported in the three disease categories: heart attack (acute myocardial infarction), heart failure, and pneumonia cases. Hospitals with incomplete submissions will have a 30-day grace period. Missing the deadline means a hospital's Medicare payments will drop by 0.4% in 2005. Two warnings from a CMS staffer: Register with your QIO by June 1 and make sure your data cover all patients in the three disease areas, not just Medicare patients. CMS will check to ensure that data are in the proper format. Some hospitals will see a 2.5% point increase in their ranking for the wage index reclassification if they submitted quality data in 2003 under Medicare's National Voluntary Hospital Reporting Quality Initiative.

    Back to top


    What new treatment regimens could look like for practices

    Even with a transitional payment of 32% in 2004, physician practices that see large revenue from drug administration may need to look for new service lines beginning in 2005. Many practices already plan to shift treatment regimens due to the MMA. For example, some plan to hold infusions during lunch. Others will shift to treatments with lower infusion time. Peyton Howell, MHA, president of the Lash Group in Charlotte, NC, offers the following lung cancer (carbo/taxol) treatment regimen scenario. Consider how it will look under Medicare reform:

    Regimen: Carboplatin AUC = 6 and Taxol 175 mg/m2 Administration: Carboplatin, 1 hour infusion and Taxol, 3 hour infusion

    For a total of three hours, assume use of the codes 96410/94612.

    With the transitional assistance in 2004, the drug brings in $2,159.98, the administration would be $313.95, up from $147.50 in December 2003. That's a total of $2473.93. The patient's copay for this regimen would be $494.79, less than 2003.

    Back to top


    Managed care plans must create fraud and abuse control

    Much of the MMA mandates practices that some managed care plans already do, but there are also a host of "new" requirements. Three big changes are that drug plans must

    Back to top


    STUDY

    Abuse prevention part of $25 million long-term care pilot

    Patient abuse prevention training for managers and employees of long-term care facilities will be required for at least one state that will participate later this year in an HHS-run pilot program. This program is one piece of a larger study that will pay long-term care facilities to conduct criminal background checks on candidates who, if hired, would be in contact with residents. States may apply. HHS will release application criteria soon and then choose 10 states. The states picked must make sure their sites are in compliance. If successful, the program could be rolled out nationally in 2008.

    Back to top


    Feature

    ED docs order tests without denial worry

    If a patient presents with leg pain in a hospital emergency department (ED) and the physicians want to rule out thrombus (a blood clot), under the MMA, they can order a lower extremity Doppler study without worrying whether the insurance payer will deny the claim. This is good news for ED physicians who, under the Emergency Medical Treatment and Labor Act, must treat and stabilize all presenting patients.

    Medicare contractors must pay for this test, no matter the outcome. Under the old Medicare rules, the payer would deny the claim if the Doppler study showed that the patient did not have thrombus. A data quality coordinator for a hospital in the southwest says EDs should consider these tests as regularly covered. "In the old days, these tests were going in the uncovered column, [but] that doesn't need to happen anymore," says the coordinator.

    For the first time, payers must decide whether the item or service ordered by the ED physician is reasonable or necessary based on the same information that the ED physician has at the time of treatment-information such as presenting symptoms and complaints.

    What's more, payers can no longer take into account the frequency with which the physician provides the item or service before or after the admission or visit. There's no real threat of abuse here, says Diana Luca, MS, chemistry lab supervisor at St. Vincent's Hospital in Bridgeport, CT. "They're ordering these tests already-there's no blanket ordering of panels."

    From a practical standpoint, hospital EDs should work closely with their fiscal intermediaries to make sure they are both are on the same page. Also, hold inservices with your physicians, medical record reviewers, and coders so each group understands the new rule.

    Back to top


    NEED TO CONTACT US?

    Bryan Cote
    Executive Editor
    E-mail address: bcote@hcpro.com

    Most Popular

    Related Articles